Aurobindo Pharma Q1 Results: Net profit rises 61.3% to ₹918 crore, revenue up 10.5% YoY

Aurobindo Pharma Q1 Results: Aurobindo Pharma released its April-June quarter results for fiscal 2024-25 (Q1FY25) on August 10, reporting a rise of 61.3 per cent in net profit at ₹918 crore, compared to ₹569 crore in the corresponding period last year. The pharma major's revenue from operations during the first quarter of current fiscal stood at ₹7,567 crore, registering a rise of 10.5 per cent, compared to ₹6,850 crore in the year-ago period.

On the operating front, the Hyderabad-based drug maker's earnings before interest, taxes, depreciation, and amortization (EBITDA) during the June quarter rose 41 per cent to ₹1,620 crore, compared to ₹1,150 crore in the same period last year. Margin rose 21.4 per cent compared to 16.8 per cent in the year-ago period.

Also Read: Aurobindo Pharma has growth levers, but stock factors brighter picture

Aurobindo Pharma Q1 Results: Key Metrics

The rise in net profit was aided by strong sales across markets. US formulations (excluding Puerto Rico) revenue increased by 13.3 per cent year-on-year (YoY) to ₹3,555 crore. Europe formulations revenue increased by 7.9 per cent YoY to ₹1,982 crore. The growth markets revenue increased by 49.2 per cent YoY to ₹709 crore. Domestic formulation sales in the quarter stood at ₹61 crore.

Active Pharmaceutical Ingredients (API) revenue grew by 5.6 per cent YoY to ₹1,092 crore in the June quarter. The research & development (R&D) spend was ₹339 crore in the June quarter at 4.5 per cent of revenues. The pharma major received final approval for 10 ANDAs including one specialty and injectable product from the USFDA. 

Also Read: Aurobindo Pharma share price rises 6% to 52-week high. Board meeting on 18 July, 2024 to consider share buyback

The basic and diluted EPS grew by 61.4 per cent YoY to ₹15.69 per share. The total formulations revenue increased by 14.6 per cent YoY to ₹6,475 crore in the June quarter. On Friday, shares of Aurobindo Pharma settled 2.18 per cent lower at ₹1,447.15 apiece on the BSE.

"We are pleased with our continued strong performance this quarter, with a significant top-line growth across all our business segments," Aurobindo Pharma Vice-Chairman and Managing Director K Nithyananda Reddy stated.

The profitability was sustained by improved gross margins and operational efficiencies, while ramping up our recently commercialised plants, he added. "We are confident in our ability to achieve our growth targets for FY25," Reddy said.

Last month, Aurobindo Pharma announced that its board has approved a share buyback plan of up to ₹750 crore. The company's board has approved the buyback of up to 51,36,986 shares representing up to 0.88 per cent of the total paid-up equity share capital, Aurobindo Pharma said in a regulatory filing.

The company will buy the shares at ₹1,460 apiece for an aggregate amount of up to ₹750 crore, it added. The drug firm said July 30 has been fixed as the record date for the ₹750-crore share buyback scheme through the tender offer route.